Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAT study of CER-001 in acute coronary syndrome
NL-OMON42661Phase 2Active, not recruiting
- Sponsor
- ABIONYX Pharma
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CER-001 in acute coronary syndrome (ACS) and coronary arteriosclerosis, sponsored by ABIONYX Pharma. Started Aug 2015; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON42661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42661.